Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2021 Dec 27

PMID 34956561

Citations 10

Authors

Yinhua Wang

Xiuhua Shi

Qinghua Qi

Bin Ye

Zhaoling Zou

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers.

Methods: 88 patients with advanced NSCLC treated in the Oncology Department of our hospital from December 2018 to December 2019 were selected as research subjects and randomly and equally split into the single treatment group (STG) and combined treatment group (CTG). The levels of serum tumor markers after treatment were detected in both groups, and the incidence of adverse reactions during treatment was recorded.

Results: Compared with the STG, CTG achieved obviously higher total effective rate ( < 0.05), lower total incidence of adverse reactions ( < 0.05), lower levels of serum tumor markers and average CFS score ( < 0.001), and higher average KPS score ( < 0.001).

Conclusion: Application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced NSCLC can effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients, with a better effect than that of simple anlotinib treatment. In addition, further research of the combined treatment is helpful to establish a better therapeutic regimen for patients with advanced NSCLC.

Citing Articles

Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.

Maimaitiyiming N, Li Y, Cao Y, Li Y Ther Adv Med Oncol. 2024; 16:17588359241284904.

PMID: 39376584 PMC: 11457245. DOI: 10.1177/17588359241284904.

Efficacy and safety of PD-1 monoclonal antibody combined with interferon-alpha 1b and anlotinib hydrochloride as the second-line therapy in patients with unresectable advanced melanoma: A retrospective study.

Zhao B, Zhang M, Tang J, Zou D, Liu F, Shi Q Cancer Med. 2024; 13(16):e70087.

PMID: 39166495 PMC: 11337113. DOI: 10.1002/cam4.70087.

Effectiveness of PD1/PD-L1 combined with anti-angiogenic drugs in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis.

Duan X, Liu X, Chen R, Pu Y J Res Med Sci. 2024; 29:7.

PMID: 38524742 PMC: 10956568. DOI: 10.4103/jrms.jrms_166_23.

Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.

Liu L, Zhang S, Yang H, Zhou C, Xiong Y, Yang N Lipids Health Dis. 2024; 23(1):16.

PMID: 38218878 PMC: 10787985. DOI: 10.1186/s12944-023-01960-7.

Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.

Zhu J, Yu Y, Mei J, Chen S, Li J, Jiang S Front Immunol. 2023; 14:1278573.

PMID: 38124737 PMC: 10731289. DOI: 10.3389/fimmu.2023.1278573.

References

Gubens M, Sequist L, Stevenson J, Powell S, Villaruz L, Gadgeel S . Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019; 130:59-66. DOI: 10.1016/j.lungcan.2018.12.015. View

Papadimitrakopoulou V, Han J, Ahn M, Ramalingam S, Delmonte A, Hsia T . Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2019; 126(2):373-380. DOI: 10.1002/cncr.32503. View

Zheng S, Cui H, Duan H, Peng Y, Li Q, Sun C . The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis. Clin Transl Oncol. 2019; 22(7):1146-1154. PMC: 7260274. DOI: 10.1007/s12094-019-02241-5. View

Zhang Y, Jia B, Li J, Xu X . Anlotinib in treatment of an elderly patient with recurrent advanced SCLC. Tumori. 2020; 106(6):NP36-NP40. DOI: 10.1177/0300891619900673. View

Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H . Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest New Drugs. 2019; 38(1):211-218. DOI: 10.1007/s10637-019-00882-5. View

Khozin S, Miksad R, Adami J, Boyd M, Brown N, Gossai A . Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019; 125(22):4019-4032. PMC: 6899461. DOI: 10.1002/cncr.32383. View

Deng H, Li B, Li L, Peng J, Lv T, Liu Y . Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer. Pathol Res Pract. 2019; 215(12):152695. DOI: 10.1016/j.prp.2019.152695. View

Ito H, Matsuo Y, Ohtsu S, Nishimura T, Terada Y, Sakamoto T . Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. Int J Clin Oncol. 2019; 25(2):274-281. DOI: 10.1007/s10147-019-01566-z. View

Rebuzzi S, Perrone F, Bersanelli M, Bregni G, Milella M, Buti S . Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Mol Diagn. 2019; 20(2):169-185. DOI: 10.1080/14737159.2019.1680286. View

10.

Visser S, Koolen S, de Bruijn P, Belderbos H, Cornelissen R, Mathijssen R . Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. Eur J Cancer. 2019; 121:64-73. DOI: 10.1016/j.ejca.2019.08.012. View

11.

Wei Z, Yang X, Ye X, Huang G, Li W, Han X . Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer. J Cancer Res Ther. 2020; 15(7):1629-1634. DOI: 10.4103/jcrt.JCRT_990_19. View

12.

Lou Y, Marin-Acevedo J, Vishnu P, Manochakian R, Dholaria B, Soyano A . Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019; 11(7):577-584. DOI: 10.2217/imt-2018-0128. View

13.

Smit H, Aerts J, van den Heuvel M, Hiltermann T, Bahce I, Smit E . Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. Lung Cancer. 2020; 140:107-112. DOI: 10.1016/j.lungcan.2019.12.011. View

14.

Li X, Zhao X, Abbas M, Wang L, Li C, Liu S . Comparative effectiveness study of single high-dose cisplatin with fractionated doses cisplatin in first-line therapy for treatment-naive Chinese patients with advanced non-small-cell lung cancer. Curr Probl Cancer. 2019; 43(6):100466. DOI: 10.1016/j.currproblcancer.2019.01.007. View

15.

Gao Z, Shang Y, Wang X, Ma Y, Yang F, Wang J . Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol. Thorac Cancer. 2019; 10(5):1310-1315. PMC: 6501042. DOI: 10.1111/1759-7714.13031. View

16.

Yang Y, Chen K, Zhou Y, Hu Z, Chen S, Huang Y . Application of serum microRNA-9-5p, 21-5p, and 223-3p combined with tumor markers in the diagnosis of non-small-cell lung cancer in Yunnan in southwestern China. Onco Targets Ther. 2018; 11:587-597. PMC: 5796463. DOI: 10.2147/OTT.S152957. View

17.

Singh B, Marshall J, He A . Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. Oncologist. 2020; 25(3):197-202. PMC: 7066712. DOI: 10.1634/theoncologist.2018-0304. View

18.

Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y . The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer. 2019; 130:159-161. DOI: 10.1016/j.lungcan.2019.02.011. View

19.

Chen Z, Huang L, Zhu B . Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer. Dis Markers. 2019; 2018:9845123. PMC: 6311751. DOI: 10.1155/2018/9845123. View

20.

Aggarwal C, Cohen R, Yu E, Hwang W, Bauml J, Alley E . Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study. Clin Lung Cancer. 2017; 19(2):157-162. DOI: 10.1016/j.cllc.2017.10.007. View